142 Demonstrating the role of spatial contexture in determining response to immune check point inhibitors using a tumor histoculture platform
BackgroundBaseline signatures have so far failed to accurately predict response to immune checkpoint inhibitors. A model that mimics the clinical response of tumor immune microenvironment (TiME) upon treatment in culture, would dramatically improve the chances of identifying true responders. Tumor h...
Gespeichert in:
Veröffentlicht in: | Journal for immunotherapy of cancer 2022-11, Vol.10 (Suppl 2), p.A155-A155 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | A155 |
---|---|
container_issue | Suppl 2 |
container_start_page | A155 |
container_title | Journal for immunotherapy of cancer |
container_volume | 10 |
creator | Sankaran, Satish Oliyarasi, M Rajashekar, M Malhotra, Ritu Jaganathan, Kowshik Gowri, Shankar K Vasanth, K Manjula, B V Ganesh, MS Amritha Prabha Prakash, B V Prakash, C Jaya Chakraborty, Arjun Syamkumar, V Das, Biswajit Satish, Aditi Basak, Nandini |
description | BackgroundBaseline signatures have so far failed to accurately predict response to immune checkpoint inhibitors. A model that mimics the clinical response of tumor immune microenvironment (TiME) upon treatment in culture, would dramatically improve the chances of identifying true responders. Tumor histocultures capture the complex interactions between various tumor microenvironment components effectively. They retain the immune cell repertoire along with spatial context, both of which are adequately represented in FarcastTM TiME histoculture platform.MethodsFarcastTM head and neck squamous cell carcinoma histoculture platform was used to evaluate response to treatment with anti-PD1 (Nivolumab) alone or in combination with anti-CTLA4 (Ipilimumab) in culture. Multiple assays including spatial analysis was performed post-treatment.ResultsInterferon gamma (INFg) cytokine release, that classically defines T- cell response, was used to stratify samples for response to treatment with Nivolumab (n=45). Histopathological evaluation revealed that 4 of 45 (9%) samples showed an increase in tumor infiltrating immune cells by 1.5 folds, with a concomitant increase in IFNg secretion (Log2FC ± SD,1.67 ± 0.8), and CD8+GranzymeB+ cells estimated by flow cytometry. Three out of these 4 samples showed an increase in tumoricidal response. To capture the complex spatial interplay between TiME components and the intra-cellular signals that determine response, a 72-protein marker GeoMx DSP (nanoString) panel was used on two samples (one recurrent and a primary) treated with Nivolumab. panCK was used for tumor segmentation. An increased expression of FoxP3 (Treg marker), IDO and phosphorylated tumor markers was observed in the recurrent sample within the tumor nest, suggestive of immune suppressive microenvironment post treatment. Interestingly, the primary sample exhibited increase in checkpoint and T-cell costimulatory molecules within the tumor nest along with a significant decrease in FoxP3 and tumor marker EGFR, suggestive of enhanced T- cell mediated tumor cytotoxicity. To map the relative spatial distribution of CD8+ and FoxP3+ cell populations, multiplex IHC assay was performed, and data analyzed using QuPath. Decrease in distance between CD8+ cells from tumor nest with a concomitant increase in distance between FoxP3+ and CD8+ cells were observed in a high IFNg and GranzymeB secreting sample.ConclusionsIn summary, our data suggests that though IFNg secretion was observed |
doi_str_mv | 10.1136/jitc-2022-SITC2022.0142 |
format | Article |
fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2840812431</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2840812431</sourcerecordid><originalsourceid>FETCH-LOGICAL-p772-2b6f71ecc6ecff2da2ca1e65a28f5e8e14606d6b49244fc2108d09dae6cd82363</originalsourceid><addsrcrecordid>eNotjU1LAzEYhIMgWGp_gwHPW5M32zQ9Sv2Eggd7L2n2jZu6m6z5AI9ePPsf_SVu1dMMwzMzhFxwNudcyKuDy6YCBlA9P27XRzNnvIYTMgG24NVo5RmZpXRgjHEmhFJqQr7G-Pvj8wb74FOOOjv_QnOLNIYOabA0DWOmO2qCz_ieS0TqPG0wY-ydP9IR0zCWkeZAXd8Xj9S0aF7pEJzPI926vcshJlrSkdc0lz5E2rqUgynd7-bQ6WxD7M_JqdVdwtm_Tsn27na7fqg2T_eP6-tNNSyXUMFe2iVHYyQaa6HRYDRHudCg7AIV8loy2ch9vYK6tgY4Uw1bNRqlaRQIKabk8m92iOGtYMq7QyjRj487UDVTHGrBxQ_OJGv6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2840812431</pqid></control><display><type>article</type><title>142 Demonstrating the role of spatial contexture in determining response to immune check point inhibitors using a tumor histoculture platform</title><source>BMJ Open Access Journals</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Sankaran, Satish ; Oliyarasi, M ; Rajashekar, M ; Malhotra, Ritu ; Jaganathan, Kowshik ; Gowri, Shankar K ; Vasanth, K ; Manjula, B V ; Ganesh, MS ; Amritha Prabha ; Prakash, B V ; Prakash, C Jaya ; Chakraborty, Arjun ; Syamkumar, V ; Das, Biswajit ; Satish, Aditi ; Basak, Nandini</creator><creatorcontrib>Sankaran, Satish ; Oliyarasi, M ; Rajashekar, M ; Malhotra, Ritu ; Jaganathan, Kowshik ; Gowri, Shankar K ; Vasanth, K ; Manjula, B V ; Ganesh, MS ; Amritha Prabha ; Prakash, B V ; Prakash, C Jaya ; Chakraborty, Arjun ; Syamkumar, V ; Das, Biswajit ; Satish, Aditi ; Basak, Nandini</creatorcontrib><description>BackgroundBaseline signatures have so far failed to accurately predict response to immune checkpoint inhibitors. A model that mimics the clinical response of tumor immune microenvironment (TiME) upon treatment in culture, would dramatically improve the chances of identifying true responders. Tumor histocultures capture the complex interactions between various tumor microenvironment components effectively. They retain the immune cell repertoire along with spatial context, both of which are adequately represented in FarcastTM TiME histoculture platform.MethodsFarcastTM head and neck squamous cell carcinoma histoculture platform was used to evaluate response to treatment with anti-PD1 (Nivolumab) alone or in combination with anti-CTLA4 (Ipilimumab) in culture. Multiple assays including spatial analysis was performed post-treatment.ResultsInterferon gamma (INFg) cytokine release, that classically defines T- cell response, was used to stratify samples for response to treatment with Nivolumab (n=45). Histopathological evaluation revealed that 4 of 45 (9%) samples showed an increase in tumor infiltrating immune cells by 1.5 folds, with a concomitant increase in IFNg secretion (Log2FC ± SD,1.67 ± 0.8), and CD8+GranzymeB+ cells estimated by flow cytometry. Three out of these 4 samples showed an increase in tumoricidal response. To capture the complex spatial interplay between TiME components and the intra-cellular signals that determine response, a 72-protein marker GeoMx DSP (nanoString) panel was used on two samples (one recurrent and a primary) treated with Nivolumab. panCK was used for tumor segmentation. An increased expression of FoxP3 (Treg marker), IDO and phosphorylated tumor markers was observed in the recurrent sample within the tumor nest, suggestive of immune suppressive microenvironment post treatment. Interestingly, the primary sample exhibited increase in checkpoint and T-cell costimulatory molecules within the tumor nest along with a significant decrease in FoxP3 and tumor marker EGFR, suggestive of enhanced T- cell mediated tumor cytotoxicity. To map the relative spatial distribution of CD8+ and FoxP3+ cell populations, multiplex IHC assay was performed, and data analyzed using QuPath. Decrease in distance between CD8+ cells from tumor nest with a concomitant increase in distance between FoxP3+ and CD8+ cells were observed in a high IFNg and GranzymeB secreting sample.ConclusionsIn summary, our data suggests that though IFNg secretion was observed in multiple samples post treatment, spatial contexture influenced T-cell response mediated tumor cytotoxicity. Farcast TiME thus provides a unique platform that can combine spatial dynamics of immune cells overlaid with bulk data, providing important insights into understanding underlying mechanisms that counter T-cell response to immune check point inhibitors.AcknowledgementsTechnical support from nanoString for performing the GeoMx DSP experiment and analysis is acknowledged.Ethics ApprovalAll patient samples used in this study was obtained with prior approvals from individual institutional review boards of participating hospitals.</description><identifier>EISSN: 2051-1426</identifier><identifier>DOI: 10.1136/jitc-2022-SITC2022.0142</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Cytotoxicity ; Immunotherapy</subject><ispartof>Journal for immunotherapy of cancer, 2022-11, Vol.10 (Suppl 2), p.A155-A155</ispartof><rights>2022 Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids></links><search><creatorcontrib>Sankaran, Satish</creatorcontrib><creatorcontrib>Oliyarasi, M</creatorcontrib><creatorcontrib>Rajashekar, M</creatorcontrib><creatorcontrib>Malhotra, Ritu</creatorcontrib><creatorcontrib>Jaganathan, Kowshik</creatorcontrib><creatorcontrib>Gowri, Shankar K</creatorcontrib><creatorcontrib>Vasanth, K</creatorcontrib><creatorcontrib>Manjula, B V</creatorcontrib><creatorcontrib>Ganesh, MS</creatorcontrib><creatorcontrib>Amritha Prabha</creatorcontrib><creatorcontrib>Prakash, B V</creatorcontrib><creatorcontrib>Prakash, C Jaya</creatorcontrib><creatorcontrib>Chakraborty, Arjun</creatorcontrib><creatorcontrib>Syamkumar, V</creatorcontrib><creatorcontrib>Das, Biswajit</creatorcontrib><creatorcontrib>Satish, Aditi</creatorcontrib><creatorcontrib>Basak, Nandini</creatorcontrib><title>142 Demonstrating the role of spatial contexture in determining response to immune check point inhibitors using a tumor histoculture platform</title><title>Journal for immunotherapy of cancer</title><description>BackgroundBaseline signatures have so far failed to accurately predict response to immune checkpoint inhibitors. A model that mimics the clinical response of tumor immune microenvironment (TiME) upon treatment in culture, would dramatically improve the chances of identifying true responders. Tumor histocultures capture the complex interactions between various tumor microenvironment components effectively. They retain the immune cell repertoire along with spatial context, both of which are adequately represented in FarcastTM TiME histoculture platform.MethodsFarcastTM head and neck squamous cell carcinoma histoculture platform was used to evaluate response to treatment with anti-PD1 (Nivolumab) alone or in combination with anti-CTLA4 (Ipilimumab) in culture. Multiple assays including spatial analysis was performed post-treatment.ResultsInterferon gamma (INFg) cytokine release, that classically defines T- cell response, was used to stratify samples for response to treatment with Nivolumab (n=45). Histopathological evaluation revealed that 4 of 45 (9%) samples showed an increase in tumor infiltrating immune cells by 1.5 folds, with a concomitant increase in IFNg secretion (Log2FC ± SD,1.67 ± 0.8), and CD8+GranzymeB+ cells estimated by flow cytometry. Three out of these 4 samples showed an increase in tumoricidal response. To capture the complex spatial interplay between TiME components and the intra-cellular signals that determine response, a 72-protein marker GeoMx DSP (nanoString) panel was used on two samples (one recurrent and a primary) treated with Nivolumab. panCK was used for tumor segmentation. An increased expression of FoxP3 (Treg marker), IDO and phosphorylated tumor markers was observed in the recurrent sample within the tumor nest, suggestive of immune suppressive microenvironment post treatment. Interestingly, the primary sample exhibited increase in checkpoint and T-cell costimulatory molecules within the tumor nest along with a significant decrease in FoxP3 and tumor marker EGFR, suggestive of enhanced T- cell mediated tumor cytotoxicity. To map the relative spatial distribution of CD8+ and FoxP3+ cell populations, multiplex IHC assay was performed, and data analyzed using QuPath. Decrease in distance between CD8+ cells from tumor nest with a concomitant increase in distance between FoxP3+ and CD8+ cells were observed in a high IFNg and GranzymeB secreting sample.ConclusionsIn summary, our data suggests that though IFNg secretion was observed in multiple samples post treatment, spatial contexture influenced T-cell response mediated tumor cytotoxicity. Farcast TiME thus provides a unique platform that can combine spatial dynamics of immune cells overlaid with bulk data, providing important insights into understanding underlying mechanisms that counter T-cell response to immune check point inhibitors.AcknowledgementsTechnical support from nanoString for performing the GeoMx DSP experiment and analysis is acknowledged.Ethics ApprovalAll patient samples used in this study was obtained with prior approvals from individual institutional review boards of participating hospitals.</description><subject>Cytotoxicity</subject><subject>Immunotherapy</subject><issn>2051-1426</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNotjU1LAzEYhIMgWGp_gwHPW5M32zQ9Sv2Eggd7L2n2jZu6m6z5AI9ePPsf_SVu1dMMwzMzhFxwNudcyKuDy6YCBlA9P27XRzNnvIYTMgG24NVo5RmZpXRgjHEmhFJqQr7G-Pvj8wb74FOOOjv_QnOLNIYOabA0DWOmO2qCz_ieS0TqPG0wY-ydP9IR0zCWkeZAXd8Xj9S0aF7pEJzPI926vcshJlrSkdc0lz5E2rqUgynd7-bQ6WxD7M_JqdVdwtm_Tsn27na7fqg2T_eP6-tNNSyXUMFe2iVHYyQaa6HRYDRHudCg7AIV8loy2ch9vYK6tgY4Uw1bNRqlaRQIKabk8m92iOGtYMq7QyjRj487UDVTHGrBxQ_OJGv6</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>Sankaran, Satish</creator><creator>Oliyarasi, M</creator><creator>Rajashekar, M</creator><creator>Malhotra, Ritu</creator><creator>Jaganathan, Kowshik</creator><creator>Gowri, Shankar K</creator><creator>Vasanth, K</creator><creator>Manjula, B V</creator><creator>Ganesh, MS</creator><creator>Amritha Prabha</creator><creator>Prakash, B V</creator><creator>Prakash, C Jaya</creator><creator>Chakraborty, Arjun</creator><creator>Syamkumar, V</creator><creator>Das, Biswajit</creator><creator>Satish, Aditi</creator><creator>Basak, Nandini</creator><general>BMJ Publishing Group LTD</general><scope>K9.</scope></search><sort><creationdate>20221101</creationdate><title>142 Demonstrating the role of spatial contexture in determining response to immune check point inhibitors using a tumor histoculture platform</title><author>Sankaran, Satish ; Oliyarasi, M ; Rajashekar, M ; Malhotra, Ritu ; Jaganathan, Kowshik ; Gowri, Shankar K ; Vasanth, K ; Manjula, B V ; Ganesh, MS ; Amritha Prabha ; Prakash, B V ; Prakash, C Jaya ; Chakraborty, Arjun ; Syamkumar, V ; Das, Biswajit ; Satish, Aditi ; Basak, Nandini</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p772-2b6f71ecc6ecff2da2ca1e65a28f5e8e14606d6b49244fc2108d09dae6cd82363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cytotoxicity</topic><topic>Immunotherapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sankaran, Satish</creatorcontrib><creatorcontrib>Oliyarasi, M</creatorcontrib><creatorcontrib>Rajashekar, M</creatorcontrib><creatorcontrib>Malhotra, Ritu</creatorcontrib><creatorcontrib>Jaganathan, Kowshik</creatorcontrib><creatorcontrib>Gowri, Shankar K</creatorcontrib><creatorcontrib>Vasanth, K</creatorcontrib><creatorcontrib>Manjula, B V</creatorcontrib><creatorcontrib>Ganesh, MS</creatorcontrib><creatorcontrib>Amritha Prabha</creatorcontrib><creatorcontrib>Prakash, B V</creatorcontrib><creatorcontrib>Prakash, C Jaya</creatorcontrib><creatorcontrib>Chakraborty, Arjun</creatorcontrib><creatorcontrib>Syamkumar, V</creatorcontrib><creatorcontrib>Das, Biswajit</creatorcontrib><creatorcontrib>Satish, Aditi</creatorcontrib><creatorcontrib>Basak, Nandini</creatorcontrib><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Journal for immunotherapy of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sankaran, Satish</au><au>Oliyarasi, M</au><au>Rajashekar, M</au><au>Malhotra, Ritu</au><au>Jaganathan, Kowshik</au><au>Gowri, Shankar K</au><au>Vasanth, K</au><au>Manjula, B V</au><au>Ganesh, MS</au><au>Amritha Prabha</au><au>Prakash, B V</au><au>Prakash, C Jaya</au><au>Chakraborty, Arjun</au><au>Syamkumar, V</au><au>Das, Biswajit</au><au>Satish, Aditi</au><au>Basak, Nandini</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>142 Demonstrating the role of spatial contexture in determining response to immune check point inhibitors using a tumor histoculture platform</atitle><jtitle>Journal for immunotherapy of cancer</jtitle><date>2022-11-01</date><risdate>2022</risdate><volume>10</volume><issue>Suppl 2</issue><spage>A155</spage><epage>A155</epage><pages>A155-A155</pages><eissn>2051-1426</eissn><abstract>BackgroundBaseline signatures have so far failed to accurately predict response to immune checkpoint inhibitors. A model that mimics the clinical response of tumor immune microenvironment (TiME) upon treatment in culture, would dramatically improve the chances of identifying true responders. Tumor histocultures capture the complex interactions between various tumor microenvironment components effectively. They retain the immune cell repertoire along with spatial context, both of which are adequately represented in FarcastTM TiME histoculture platform.MethodsFarcastTM head and neck squamous cell carcinoma histoculture platform was used to evaluate response to treatment with anti-PD1 (Nivolumab) alone or in combination with anti-CTLA4 (Ipilimumab) in culture. Multiple assays including spatial analysis was performed post-treatment.ResultsInterferon gamma (INFg) cytokine release, that classically defines T- cell response, was used to stratify samples for response to treatment with Nivolumab (n=45). Histopathological evaluation revealed that 4 of 45 (9%) samples showed an increase in tumor infiltrating immune cells by 1.5 folds, with a concomitant increase in IFNg secretion (Log2FC ± SD,1.67 ± 0.8), and CD8+GranzymeB+ cells estimated by flow cytometry. Three out of these 4 samples showed an increase in tumoricidal response. To capture the complex spatial interplay between TiME components and the intra-cellular signals that determine response, a 72-protein marker GeoMx DSP (nanoString) panel was used on two samples (one recurrent and a primary) treated with Nivolumab. panCK was used for tumor segmentation. An increased expression of FoxP3 (Treg marker), IDO and phosphorylated tumor markers was observed in the recurrent sample within the tumor nest, suggestive of immune suppressive microenvironment post treatment. Interestingly, the primary sample exhibited increase in checkpoint and T-cell costimulatory molecules within the tumor nest along with a significant decrease in FoxP3 and tumor marker EGFR, suggestive of enhanced T- cell mediated tumor cytotoxicity. To map the relative spatial distribution of CD8+ and FoxP3+ cell populations, multiplex IHC assay was performed, and data analyzed using QuPath. Decrease in distance between CD8+ cells from tumor nest with a concomitant increase in distance between FoxP3+ and CD8+ cells were observed in a high IFNg and GranzymeB secreting sample.ConclusionsIn summary, our data suggests that though IFNg secretion was observed in multiple samples post treatment, spatial contexture influenced T-cell response mediated tumor cytotoxicity. Farcast TiME thus provides a unique platform that can combine spatial dynamics of immune cells overlaid with bulk data, providing important insights into understanding underlying mechanisms that counter T-cell response to immune check point inhibitors.AcknowledgementsTechnical support from nanoString for performing the GeoMx DSP experiment and analysis is acknowledged.Ethics ApprovalAll patient samples used in this study was obtained with prior approvals from individual institutional review boards of participating hospitals.</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/jitc-2022-SITC2022.0142</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | EISSN: 2051-1426 |
ispartof | Journal for immunotherapy of cancer, 2022-11, Vol.10 (Suppl 2), p.A155-A155 |
issn | 2051-1426 |
language | eng |
recordid | cdi_proquest_journals_2840812431 |
source | BMJ Open Access Journals; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Cytotoxicity Immunotherapy |
title | 142 Demonstrating the role of spatial contexture in determining response to immune check point inhibitors using a tumor histoculture platform |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T13%3A46%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=142%E2%80%85Demonstrating%20the%20role%20of%20spatial%20contexture%20in%20determining%20response%20to%20immune%20check%20point%20inhibitors%20using%20a%20tumor%20histoculture%20platform&rft.jtitle=Journal%20for%20immunotherapy%20of%20cancer&rft.au=Sankaran,%20Satish&rft.date=2022-11-01&rft.volume=10&rft.issue=Suppl%202&rft.spage=A155&rft.epage=A155&rft.pages=A155-A155&rft.eissn=2051-1426&rft_id=info:doi/10.1136/jitc-2022-SITC2022.0142&rft_dat=%3Cproquest%3E2840812431%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2840812431&rft_id=info:pmid/&rfr_iscdi=true |